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Abstract
Background: Environmental exposure is a likely risk factor for the development of pulmonary Mycobacterium avium
complex (MAC) disease. The influence of environmental exposure on the response to antimicrobial treatment and
relapse is unknown.
Methods: We recruited 72 patients with pulmonary MAC disease (male [female], 18 [54]; age, 61.7 ± 10.3 years)
who initiated and completed standard three-drug regimens for more than 12 months between January 2007 and
December 2011. The factors associated with sputum conversion, relapse and treatment success without relapse
were retrospectively evaluated after adjustments for confounding predictors.
Results: Fifty-two patients (72.2%) demonstrated sputum conversion, and 15 patients (28.8%) relapsed. A total
of 37 patients (51.4%) demonstrated treatment success. Sputum conversion was associated with negative smears
(odds ratio [OR], 3.89; 95% confidence interval [CI], 1.27-12.60; P = 0.02). A relapse occurred in patients with low soil
exposure after the start of treatment less frequently than in patients with high soil exposure (7/42 [16.7%] vs. 8/10
[80.0%], P = 0.0003). Treatment success was associated with low soil exposure after the beginning of treatment (OR,
13.46; 95% CI, 3.24-93.43; P = 0.0001) and a negative smear (OR, 2.97; 95% CI, 1.02-9.13; P = 0.047).
Conclusion: Low soil exposure was independently associated with better microbiological outcomes in
patients with pulmonary MAC disease after adjusting for confounding clinical, microbiological and radiographic
findings.
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Background
Although the prevalence of pulmonary Mycobacterium
avium complex (MAC) disease has increased in several
countries [1-3], the treatment outcomes are unsatisfactory.
Even after treatment with clarithromycin- or azithromycin-
containing multidrug therapy, a series of pooled studies
reported that the sputum conversion rate and the
cure rate of pulmonary MAC disease were 68% and 56%,
respectively [4].
Various clinical factors, including female gender [5],
negative smears [6,7], and no previous treatment for
MAC [6], were reported to be associated with sputum
conversion. In the case of a three-times-weekly regimen,
a reduction in sputum colony counts was associated
with non-cavitary disease, negative smears, no previous
treatment for MAC, older age and a longer duration of
ethambutol use (for >5 months) [8]. Furthermore, a
higher dose of clarithromycin (≥500 mg/day) and the
addition of streptomycin to the standard three-drug
treatment including clarithromycin, ethambutol and
rifamycin were associated with a better microbiological
response [7,9-11].
Relapse after successful treatments with sputum
conversion is often observed (8.3-30.0%) [4]. Wallace et al.
reported polyclonal infections in human immunodeficiency
virus (HIV)-negative patients with pulmonary MAC disease
[12] and reinfection by new MAC genotypes after the
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completion of macrolide therapy [13]. Polyclonal infection
could contribute to relapse (reactivation), and the exposure
of patients who are susceptible to mycobacterial infection
to environmental mycobacteria could also contribute
to reinfection (new infection) [13].
Environmental exposure from water and soil in the
human living environment is considered the primary
route for MAC infection [14]. We reported that patients
with pulmonary MAC disease have significantly more
soil exposure than non-infected control patients after
adjustments for host traits [15] and that approximately
one-half of patients’ residential soil contained MAC
strains. The clinical and corresponding soil isolates with
identical genotypes were identified among patients with a
high soil exposure [16]. Furthermore, we recently reported
that environmental soil or water exposure was associated
with polyclonal MAC infection or mixed mycobacterial
infection [17]. These results suggested that environmental
exposure is a likely risk factor for the development or
reinfection of pulmonary MAC disease. Therefore, we
hypothesized that environmental exposures would lead to
more MAC infection and influence the responses to
antimicrobial treatments and relapse. In this study, we
evaluated the significance of environmental exposures on
the response to the standard three-drug treatment in
patients with pulmonary MAC disease after adjustments
for confounding predictors of microbiological responses.
Methods
Study population
We recruited 72 patients who met the American Thoracic
Society guidelines for the diagnosis of pulmonary MAC dis-
ease [18], had newly initiated and completed the standard
three-drug treatment (clarithromycin, rifampicin and etham-
butol) for more than 12 months between January 2007 and
December 2011, these patients and were followed for at least
2 years to define treatment success at the Kyoto University
Hospital in Japan. All of the patients received ≥600 mg/day
clarithromycin without streptomycin use and either had
negative results for serological HIV testing or no obvious
risk factors for HIV infection. The institutional review board
of Kyoto University approved the research protocol (E1999)
and waived the need for obtaining written informed consent
for all participants. We obtained written informed consent
in the case of patients offering their blood or sputum.
Data collection
Clinical data, including demographic characteristics, the
presence of underlying diseases and conditions and the
microbiological results for respiratory specimens, were
retrospectively collected. All of the patients completed
a questionnaire about their experiences with environmen-
tal exposure, such as soil exposure from farming and gar-
dening, or with any activities involving soil exposure, such
as digging or carrying soils, turning soil with a spade,
mowing grass, planting flowers, and exposure to soil
dusts, and water exposure from taking baths or showers,
and swimming in a pool [15]; these questionnaires were
answered before or at the start of their treatments and
during or after discontinuing their treatments. Low soil
exposure and high soil exposure were defined as no
exposure or less than 2 hours per week and 2 or more
hours per week of soil-related activities, respectively [16].
At the start of the treatments or during follow-up, one
thoracic radiologist who had no prior knowledge of the
patient profiles or the results of the laboratory data
conducted chest computed tomography (CT) and/or
standard radiographs, which were assessed for the presence
of nodules, bronchiectasis and cavities.
Sputum conversion to negative status was defined as three
consecutive negative cultures after treatment induction.
Sputum relapse was defined as two consecutive positive
cultures after sputum conversion [19]. Treatment success
and treatment failure included patients who achieved
sputum conversion without relapse and patients who did
not achieve sputum conversion or relapsed after sputum
conversion, respectively.
Susceptibility to clarithromycin
The minimal inhibitory concentration (MIC) to clarithro-
mycin was determined by the broth microdilution method
with commercially manufactured plates (BrothMIC NTM,
Kyokuto, Japan). The isolates were assessed as suscep-
tible and resistant to clarithromycin if they had MICs
of ≤ 8 μg/ml and ≥32 μg/ml, respectively.
Statistical analysis
JMP version 10.0 (SAS Institute, Cary, NC, USA) was used
for all of the statistical analyses. We divided the patients
into two groups; patients with sputum conversion and
patients without sputum conversion; patients without
relapse and patients with relapse; and patients with
treatment success and patients without treatment success.
The group comparisons were made using the chi-square
test, Fisher’s exact test, and the Wilcoxon test. The
comparisons of more than two groups were performed
using an analysis of variance. Variables were included in
the multiple logistic regression analyses if the probability
values were <0.05 according to the univariate analysis.
Odds ratios (ORs) and their respective 95% confidence
intervals (CIs) were computed as estimates of relative risk.
A p-value of <0.05 was considered statistically significant.
Results
Characteristics of the pulmonary MAC patients and the
microbiological outcomes
The mean patient age was 61.7 ± 10.3 years at the start
of treatment, and females predominated (54 patients,
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75.0%). Cavities were evident in 35 patients (48.6%), of
whom 25 patients (71.4%) were non-smoking females.
Among the 15 patients (20.8%) with large cavities
(≥2 cm), 12 patients (80.0%) were non-smoking females.
The treatments were discontinued in 61 patients and
continued in 11 patients during the observation period.
Fifty-two patients (72.2%) converted to negative sputum
cultures, and 15 (28.8%) of these patients relapsed. Two
patients relapsed within the 12 months of treatment,
and 13 patients relapsed after the 12 months of treatment.
All 15 strains isolated from each of the 15 relapsed
patients were susceptible to clarithromycin. The treatment
was successful for 37 (51.4%) patients and failed for
35 patients (48.6%). One patient died during his treatment,
and one patient died after discontinuing his treatment.
Twenty-five patients experienced high soil exposure during
the observation. One patient was working as a farmer, and
the remaining 24 of these patients were gardeners. There
was no interaction between a negative smear and low
soil exposure before the treatments (P > 0.99), after
the start of the treatments (P = 0.57) or during the
observation (P = 0.89).
Factors associated with sputum conversion, relapse and
treatment success
The patients with sputum conversion had negative smears
at the start of the treatment (71.2%) and had either no
cavities or cavity sizes of <2 cm (86.5%) (Table 1). The
rates of sputum conversion were 84.1% (37/44) in the
patients with negative smears versus 53.6% (15/28) in
the patients with positive smears (P = 0.005); the sputum
conversion rate was 79.0% (45/57) in the patients with no
cavities or cavities < 2 cm in size versus 46.7% (7/15) in
the patients with cavities ≥2 cm (P = 0.01). In the multiple
logistic regression analyses, negative smears were signifi-
cantly associated with sputum conversion (OR 3.89, 95%
CI 1.27-12.60, P = 0.02, Table 2).
Low soil exposure, particularly after the start of treat-
ment (P = 0.0003), was associated with the absence of a
relapse (Table 3). A relapse was observed in only 7 of 42
patients (16.7%) who experienced low soil exposure
after the start of treatment, whereas it was observed
in 8 of 10 patients (80.0%) with high soil exposure
(OR 0.05, 95% CI 0.007-0.25, P = 0.0001).
Treatment success was associated with low soil exposure,
particularly after the start of treatment (P = 0.0002), and
negative smears at the start of treatment (P = 0.01) (Table 4).
The rates of treatment success were 63.6% (35/55) in the
patients with low soil exposure after the start of treatment
versus 11.8% (2/17) in the patients with high soil expos-
ure; the rate of treatment success was 61.4% (27/44)
in the patients with negative smears versus 35.7% (10/28)
in the patients with positive smears. In the multiple logis-
tic regression analysis, low soil exposure after the start of
treatment (OR 13.46, 95% CI 3.24-93.43, P = 0.0001) and a
negative smear (OR 2.97, 95% CI 1.02-9.13, P = 0.047) were
significantly associated with treatment success (Table 5).
Among the 8 patients who discontinued soil exposure
after the start of treatment, 5 patients converted to negative
sputum cultures, and 1 patient relapsed. Two patients were
newly exposed to soil during the treatment, and 2 patients
were exposed after discontinuing treatment. Of these 4
patients, 2 patients converted to negative sputum cultures
and relapsed. Among the 13 patients who continued soil
exposure after the start of treatment, 8 patients converted
to negative sputum cultures, and 6 patients relapsed. More
patients who discontinued soil exposure had no relapse and
treatment success than the patients who continued or
newly began exposure (4/5, 80.0% vs. 2/10, 20.0%, respect-
ively, P = 0.09; 4/8, 50.0% vs. 2/17, 11.8%, respectively,
P = 0.06). Although more patients who began their
treatments after 2010 discontinued soil exposure than
patients who began their treatments before 2009 (6/10,
60.0% vs. 2/15, 13.3%, P = 0.03), there were no differences
in the characteristics between the 8 patients who discon-
tinued soil exposure and the 17 patients who continued or
newly began exposure.
Microbiological outcomes and their related factors in
cavitary disease
Among the 35 patients with cavities, 22 patients (62.9%)
converted to negative sputum cultures, and 4 (18.2%) of
these patients relapsed. Treatment was successful for 18
(51.4%) patients. More patients with sputum conversion
had negative smears at the start of treatments than the
patients without conversion (15/22, 68.2% vs. 3/13, 23.1%,
P = 0.01). More patients without a relapse had low soil
exposure after the start of treatment than the patients with
a relapse (18/18, 100% vs. 2/4, 50.0%, P = 0.03). Treatment
success was significantly associated with the absence of
lung disease (0/18, 0.0% vs. 5/17, 29.4%, P = 0.02). More
patients with treatment success had low soil exposure after
the start of treatment than the patients without treatment
success (18/18, 100% vs. 12/17, 70.6%, P = 0.02).
Microbiological outcomes and their related factors in
non-cavitary disease
Among the 37 nodular bronchiectasis patients without
cavities, 30 patients (81.1%) converted to negative sputum
cultures, and 11 (36.7%) of these patients relapsed.
Treatment was successful for 19 (51.4%) patients. No
factors were associated with sputum conversion. More
patients without a relapse had low soil exposure after
the start of treatment than patients with a relapse
(17/19, 89.5% vs. 5/11, 45.4%, P = 0.03). More patients
with treatment success had low soil exposure after the
start of treatment than the patients without treatment
success (17/19, 89.5% vs. 8/17, 44.4%, P = 0.004).
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Table 2 Factors associated with sputum conversion in patients with pulmonary Mycobacterium avium complex disease
Variable Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Positive smear Reference
Negative smear 4.58 (1.57-14.41) 0.005 3.89 (1.27-12.60) 0.02
Large cavity (≥2 cm) Reference
Cavity (none or <2 cm) 4.29 (1.30-14.68) 0.02 3.37 (0.95-12.26) 0.06
OR, odds ratio; CI, confidence interval.
Table 1 Characteristics of the patients with pulmonary Mycobacterium avium complex disease with or without sputum
conversion
Variable Patients with sputum conversion
(n = 52)
Patients without sputum conversion
(n = 20)
P value
Age, years 61.5 ± 10.2 62.3 ± 10.8 0.85
Gender, female (%) 38 (73.1) 16 (80.0) 0.54
Underlying disease
Lung disease 12 (23.1) 7 (35.0) 0.30
COPD 3 (5.8) 1 (5.0) >0.99
Asthma 3 (5.8) 1 (5.0) >0.99
Previous tuberculosis 2 (3.9) 3 (15.0) 0.13
Previous malignant disease 11 (21.2) 1 (5.0) 0.16
Diabetes mellitus 5 (9.6) 1 (5.0) >0.99
Collagen vascular disease 6 (11.5) 3 (15.0) 0.70
Immunosuppressive agents 2 (3.9) 3 (15.0) 0.13
Inhaled corticosteroid 2 (3.9) 0 (0.0) >0.99
Smoking status (ex or current) 11 (21.2) 3 (15.0) 0.74
Alcohol drinking habit 14 (26.9) 3 (15.0) 0.36
Environmental exposure
Low soil exposure before treatment 39 (75.0) 12 (60.0) 0.21
Low soil exposure during treatment 44 (84.6) 13 (65.0) 0.10
Low soil exposure during observation 37 (71.2) 10 (50.0) 0.09
Bathing (≥1 per day) 50 (96.2) 18 (90.0) 0.31
Shower use in a bathroom 41 (78.9) 14 (70.0) 0.43
Swimming in a pool 2 (3.9) 0 (0.0) >0.99
Laboratory findings
Negative smear 37 (71.2) 7 (35.0) 0.005
M. avium 39 (75.0) 17 (85.0) 0.60
M. intracellulare 12 (23.1) 3 (15.0)
M. avium +M. intracellulare 1 (1.9) 0 (0.0)
Radiographic findings
Any size of cavity 22 (42.3) 13 (65.0) 0.08
Large cavity (≥2 cm) 7 (13.5) 8 (40.0) 0.02
Bronchiectasis 46 (88.5) 19 (95.0) 0.66
Total length of follow-up time, months 55.6 ± 21.2 49.1 ± 16.4 0.28
COPD, chronic obstructive pulmonary disease. The data show either the numbers (%) of patients or the means ± standard deviations. Low soil exposure is defined
as no exposure or less than 2 hours per week of soil-related activities.
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Microbiological outcomes and their related factors in
M. avium disease
Among the 56 patients with M. avium disease, 39 patients
(69.6%) converted to negative sputum cultures, and 13
(33.3%) of these patients relapsed. Treatment was success-
ful for 26 (46.4%) patients. No factors were associated with
sputum conversion. More patients without a relapse had
low soil exposure after the start of treatment than the
patients with a relapse (24/26, 92.3% vs. 6/13, 46.2%,
P = 0.003). More patients with treatment success had
low soil exposure after the start of treatment than did
the patients without treatment success (24/26, 92.3%
vs. 17/30, 56.7%, P = 0.003).
Microbiological outcomes and their related factors in
M. intracellulare disease
Among the 15 patients with M. avium disease, 12 patients
(80.0%) converted to negative sputum cultures, and 2
(16.7%) of these patients relapsed. Treatment was
successful for 10 (66.7%) patients. No factors were
associated with sputum conversion, relapse or treat-
ment success. More patients without a relapse had
low soil exposure after the start of treatment than
did the patients with a relapse (10/10, 100% vs. 1/2,
50.0%, P = 0.17). More patients with treatment success
had low soil exposure after the start of treatment than the
patients without treatment success (10/10, 100% vs. 3/5,
60.0%, P = 0.10).
Discussion
In this study, we demonstrated that low environmental
soil exposure was an independent predictor of no relapse
and treatment success after adjustments for various clinical
factors involving unfavorable microbiologic responses.
Because these microbiological outcomes were better
associated with soil exposure during or after the start of
treatment rather than before treatment, the discontinuation
of soil exposure is likely to influence treatment outcomes
(Tables 3 and Table 4). Behavioral activities regarding
environmental exposure should be considered potential
confounding factors in microbiological responses in
pulmonary MAC disease.
All participants in this study received the standard
three-drug treatment for more than 12 months. The rate
of initial sputum conversion in this study was 72.2%
(52/72), which is comparable to the results from a
series of pooled studies with macrolide-containing
treatments (mean 68%, 54-84%) [4]. In several studies, a
negative smear was reported to be a better predictor
of a microbiological response [8], and it was signifi-
cantly associated with sputum conversion in this study
(Tables 1 and 2).
The population in this study predominantly consisted
of non-smoking females with nodular bronchiectatic
findings. Although approximately half of the patients
(35, 48.6%) had cavitary lesions, and 18 (25.0%) patients
had large cavitary lesions (≥2 cm) concomitant with
nodular bronchiectasis, few patients had typical apical
Table 3 Characteristics of patients with pulmonary








(n = 37) (n = 15)
Age, years 60.3 ± 11.4 64.6 ± 5.3 0.27
Gender, female (%) 28 (75.7) 10 (66.7) 0.51
Underlying disease
Lung disease 7 (18.9) 5 (33.3) 0.29
COPD 1 (2.7) 2 (13.3) 0.19
Asthma 2 (5.4) 1 (6.7) >0.99
Previous tuberculosis 2 (5.4) 0 (0.0) >0.99
Previous malignant disease 8 (21.6) 3 (20.0) >0.99
Diabetes mellitus 3 (8.1) 2 (13.3) 0.62
Collagen vascular disease 3 (8.1) 3 (20.0) 0.34
Immunosuppressive agents 1 (2.7) 1 (6.7) 0.50
Inhaled corticosteroid 1 (2.7) 1 (6.7) 0.50
Smoking status
(ex or current)
8 (21.6) 3 (20.0) >0.99
Alcohol drinking habit 8 (21.6) 6 (40.0) 0.19
Environmental exposure
Low soil exposure before
treatment
31 (83.8) 8 (53.3) 0.03
Low soil exposure after the
start of treatment
35 (94.6) 7 (46.7) 0.0003
Low soil exposure during
observation
31 (83.8) 6 (40.0) 0.005
Bathing (≥1 per day) 35 (94.6) 15 (100) >0.99
Shower use in a bathroom 29 (78.4) 12 (80.0) 0.90
Swimming in a pool 2 (5.4) 0 (0.0) >0.99
Laboratory findings
Negative smear 27 (73.0) 10 (66.7) 0.74
M. avium 26 (70.3) 13 (86.7) 0.44
M. intracellulare 10 (27.0) 2 (13.3)
M. avium +M. intracellulare 1 (2.7) 0 (0.0)
Radiographic findings
Any size of cavity 18 (48.7) 4 (26.7) 0.15
Large cavity (≥2 cm) 6 (16.2) 1 (6.7) 0.66
Bronchiectasis 34 (91.9) 12 (80.0) 0.34
Total length of follow-up
time, months
53.8 ± 20.8 60.0 ± 22.1 0.28
COPD, chronic obstructive pulmonary disease. The data show either the
numbers (%) of patients or the means ± standard deviations. Low soil
exposure is defined as no exposure or less than 2 hours per week of
soil-related activities.
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cavitary disease (male smokers with previous tuberculosis
or COPD). It was difficult to differentiate between typical
apical cavitary disease and nodular bronchiectasis disease
in these patients. We included the patients with cavities in
the cavitary disease category.
There have been conflicting reports regarding the
influence of the presence of cavitary disease on the
efficacy of sputum conversion. One study reported that
the absence of cavitary disease resulted in reduced colony
counts [8], whereas other studies showed no association
between non-cavitary disease and sputum conversion
[5,6]. In this study, a large cavity (≥2 cm), but not any
other size cavity, was a significantly unfavorable predictor
of sputum conversion.
Wallace et al. reported on reinfection by new MAC
genotypes in patients with nodular bronchiectasis [12,13].
Although there was not a statistically significant difference,
a greater amount of relapse was observed in non-cavitary
disease patients than in cavitary disease patients in this
study (Table 3). The microbiological outcomes were associ-
ated with soil exposure alone in the non-cavitary disease
patients, whereas they were associated with soil exposure
as well as clinical and microbiological factors, such as the
presence of COPD and positive sputum smears, in the
cavitary disease patients.
There were some limitations in our study. First, when
we started the enrollment of patients, we did not intervene
to prevent environmental exposure. However, we notified
the patients of our findings that soil exposure was a risk
factor of pulmonary MAC disease after 2010 [15] and sug-
gested the avoidance of soil exposure and the use of masks
when they were exposed to soil. Because we administered a
questionnaire about their experiences with environmental
exposure before or at the start of their treatments, more
patients starting their treatments after 2010 discontinued
soil exposure than patients before 2009. This difference is
likely a potential confounding variable. However, the
patient characteristics did not differ between the patients
who discontinued and those who continued soil exposure.
Second, we did not analyze the genotypes of the MAC
strains collected from the relapsed patients. Therefore, we
could not discriminate a true relapse (reactivation) from a
Table 4 Characteristics of the patients with pulmonary









(n = 37) (n = 35)
Age, years 60.3 ± 11.4 63.3 ± 8.8 0.34
Gender, female (%) 28 (75.7) 26 (74.3) 0.89
Underlying disease
Lung disease 7 (18.9) 12 (34.3) 0.14
COPD 1 (2.7) 3 (8.6) 0.35
Asthma 2 (5.4) 2 (5.7) >0.99
Previous tuberculosis 2 (5.4) 3 (8.6) 0.67
Previous malignant disease 8 (21.6) 4 (11.4) 0.25
Diabetes mellitus 3 (8.1) 3 (8.6) >0.99
Collagen vascular disease 3 (8.1) 6 (17.1) 0.30
Use of immunosuppressive
agents
1 (2.7) 4 (11.4) 0.19
Use of inhaled corticosteroid 1 (2.7) 1 (2.9) >0.99
Smoking status
(ex or current)
8 (21.6) 6 (17.1) 0.63
Alcohol drinking habit 8 (21.6) 9 (25.7) 0.78
Environmental exposure
Low soil exposure before
treatment
31 (83.8) 20 (57.1) 0.01
Low soil exposure after the
start of treatment
35 (94.6) 15 (42.9) 0.0002
Low soil exposure during
observation
31 (83.8) 16 (45.7) 0.0007
Bathing (≥1 per day) 35 (94.6) 33 (94.3) >0.99
Shower use in a bathroom 29 (78.4) 26 (74.3) 0.68
Swimming in a pool 2 (5.4) 0 (0.0) 0.49
Laboratory findings
Negative smear 27 (73.0) 17 (48.6) 0.03
M. avium 26 (70.3) 30 (85.7) 0.23
M. intracellulare 10 (27.0) 5 (14.3)
M. avium +M. intracellulare 1 (2.7) 0 (0.0)
Radiographic findings
Any size of cavity 18 (48.6) 17 (48.6) >0.99
Large cavity (≥2 cm) 6 (16.2) 9 (25.7) 0.32
Bronchiectasis 34 (91.9) 31 (88.6) 0.71
Total length of follow-up
time, months
53.8 ± 20.8 53.8 ± 19.5 0.90
COPD, chronic obstructive pulmonary disease. The data show either the numbers
(%) of patients or the means ± standard deviations. Low soil exposure is defined
as no or less than 2 hours per week of soil-related activities.
Table 5 Factors associated with treatment success in the
patients with pulmonary Mycobacterium avium complex
disease
Variable Univariate analysis Multivariate analysis










2.86 (1.09-7.87) 0.03 2.97 (1.02-9.13) 0.047
OR, odds ratio; CI, confidence interval. Low soil exposure is defined as no
exposure or less than 2 hours per week after the start of treatment.
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new infection (reinfection). Third, because of the small
sample size, there were wide confidence intervals in
the logistic regression analysis. Finally, we did not include
adherence to this regimen as a variable for these microbio-
logical outcomes. However, all the patients had regularly
visited our clinics and completed this regimen for more
than 12 months.
Conclusions
In conclusion, we demonstrated an independent association
between a low environmental soil exposure and better
microbiological outcomes, including no relapse and treat-
ment success, in patients with pulmonary MAC disease
after adjusting for confounding clinical, microbiological and
radiographic findings.
Competing interests
The author declares that they have no competing interests.
Authors’ contributions
YI designed the study. YI and TH recruited the patients. YI, TH, KF, TK and KT
collected the data. YI, TH, SI, KT and MM interpreted the data, and YI drafted
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Takeshi Higuchi for his help in determining the
susceptibility of MAC strains.
This study was supported by a Grant-in-Aid for Scientific Research by the
Japanese Society for the Promotion of Science (24591479).
Author details
1Department of Respiratory Medicine, Kyoto, Japan. 2Diagnostic Imaging and
Nuclear Medicine, Kyoto, Japan. 3Clinical Laboratory Medicine, Kyoto
University, Kyoto, Japan. 4Division of Respiratory Medicine, Takeda General
Hospital, Kyoto, Japan.
Received: 30 January 2014 Accepted: 24 September 2014
Published: 29 September 2014
References
1. Marras TK, Chedore P, Ying AM, Jamieson F: Isolation prevalence of
pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003.
Thorax 2007, 62:661–666.
2. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de
Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN: Nontuberculous mycobacterial
lung disease prevalence at four integrated health care delivery systems. Am J
Respir Crit Care Med 2010, 182:970–976.
3. Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K,
Ogata H, Kurashima A, Gemma A, Kudoh S: A steady increase in
nontuberculous mycobacteriosis mortality and estimated prevalence in
Japan. Ann Am Thorac Soc 2014, 11:1–8.
4. Field SK, Fisher D, Cowie RL: Mycobacterium avium complex pulmonary
disease in patients without HIV infection. Chest 2004, 126:566–581.
5. Fujikane T, Fujiuchi S, Yamazaki Y, Sato M, Yamamoto Y, Takeda A, Nishigaki Y,
Fujita Y, Shimizu T: Efficacy and outcomes of clarithromycin treatment for
pulmonary MAC disease. Int J Tuberc Lung Dis 2005, 9:1281–1287.
6. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A,
Suzuki K, Murayama T, Amitani R, Kuze F: Effect of clarithromycin regimen
for Mycobacterium avium complex pulmonary disease. Am J Respir Crit
Care Med 1999, 160:866–872.
7. Kobashi Y, Matsushima T: The microbiological and clinical effects of
combined therapy according to guidelines on the treatment of
pulmonary Mycobacterium avium complex disease in Japan - including a
follow-up study. Respiration 2007, 74:394–400.
8. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A:
Factors related to response to intermittent treatment of Mycobacterium
avium complex lung disease. Am J Respir Crit Care Med 2006, 173:1283–1289.
9. Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S,
Urano T, Ishii K, Miyairi M, Ishizaka A: Therapeutic effects of various initial
combinations of chemotherapy including clarithromycin against
Mycobacterium avium complex pulmonary disease. Chest 2009,
136:1569–1575.
10. Kim EY, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC, Kwon YS: Treatment
outcome of combination therapy including clarithromycin for
Mycobacterium avium complex pulmonary disease. Korean J Intern Med
2011, 26:54–59.
11. Kobashi Y, Matsushima T, Oka M: A double-blind randomized study of
aminoglycoside infusion with combined therapy for pulmonary
Mycobacterium avium complex disease. Respir Med 2007, 101:130–138.
12. Wallace RJ Jr, Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, Griffith
DE: Polyclonal Mycobacterium avium complex infections in patients with
nodular bronchiectasis. Am J Respir Crit Care Med 1998, 158:1235–1244.
13. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L,
Couch L, Girard WM, Griffith DE: Repeat positive cultures in Mycobacterium
intracellulare lung disease after macrolide therapy represent new
infections in patients with nodular bronchiectasis. J Infect Dis 2002,
186:266–273.
14. Falkinham JO 3rd: Surrounded by mycobacteria: nontuberculous
mycobacteria in the human environment. J Appl Microbiol 2009, 107:356–367.
15. Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, Fujita K, Takakura S,
Niimi A, Iinuma Y, Ichiyama S, Togashi K, Mishima M: Environmental risk
factors for pulmonary Mycobacterium avium-intracellulare complex
disease. Chest 2011, 140:723–729.
16. Fujita K, Ito Y, Hirai T, Maekawa K, Imai S, Tatsumi S, Niimi A, Iinuma Y, Ichiyama S,
Mishima M: Genetic relatedness of Mycobacterium avium-intracellulare
complex isolates from patients with pulmonary MAC disease and their
residential soils. Clin Microbiol Infect 2013, 19:537–541.
17. Fujita K, Ito Y, Hirai T, Kubo T, Maekawa K, Togashi K, Ichiyama S, Mishima M:
Association between polyclonal and mixed mycobacterial
Mycobacterium avium complex infection and environmental exposure.
Ann Am Thorac Soc 2014, 11:45–53.
18. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F,
Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K,
Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K, ATS Mycobacterial
Diseases Subcommittee; American Thoracic Society; Infectious Disease
Society of America: An official ATS/IDSA statement: diagnosis, treatment,
and prevention of nontuberculous mycobacterial diseases. Am J Respir
Crit Care Med 2007, 175:367–416.
19. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M: Relationship between
clinical efficacy of treatment of pulmonary Mycobacterium avium
complex disease and drug-sensitivity testing of Mycobacterium avium
complex isolates. J Infect Chemother 2006, 12:195–202.
doi:10.1186/1471-2334-14-522
Cite this article as: Ito et al.: The influence of environmental exposure
on the response to antimicrobial treatment in pulmonary Mycobacterial
avium complex disease. BMC Infectious Diseases 2014 14:522.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ito et al. BMC Infectious Diseases 2014, 14:522 Page 7 of 7
http://www.biomedcentral.com/1471-2334/14/522
